undamentalytics Newsletter
Sign in

Dianthus Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Dianthus Therapeutics, Inc. had total assets of $531m, total liabilities of $37.5m and shareholders' equity of $493m. It held $51.1m in cash against $0 of debt: net cash of $51.1m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents55158651322351
Receivables————000
Total current assets—53145150177281409
Total assets—54157162179374531
Accounts payable—0333510
Deferred revenue (current)————001
Total current liabilities—41014101831
Total debt0000000
Total liabilities—41220112238
Shareholders' equity−9−42146141169352493
Non-controlling interests and other (assets − liabilities − equity)—92—————
Net debt (negative = net cash)−5−51−58−65−132−23−51
Shares outstanding—35m33m39m—31m43m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: DNTH vs KRSADNTH vs MCRBCLGN vs DNTH

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Dianthus Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dianthus Therapeutics, Inc.